125 related articles for article (PubMed ID: 9687824)
1. Use-dependent electrophysiologic effects of DL-sotalol and modulation by isoproterenol in the human ventricle.
Naitoh N; Furushima H; Ohira K; Taneda K; Aizawa Y
Jpn Heart J; 1998 Mar; 39(2):153-61. PubMed ID: 9687824
[TBL] [Abstract][Full Text] [Related]
2. A comparison of electrophysiologic properties between responders and non-responders to DL-sotalol among patients with ventricular tachyarrhythmia. Importance of the lack of a reverse use-dependent effect on ventricular refractoriness to responders.
Naitoh N; Yamaura M; Tagawa M; Aizawa Y
Jpn Heart J; 1998 Sep; 39(5):619-30. PubMed ID: 9925993
[TBL] [Abstract][Full Text] [Related]
3. The effects of beta-adrenergic stimulation on the frequency-dependent electrophysiologic actions of amiodarone and sematilide in humans.
Sager PT; Follmer C; Uppal P; Pruitt C; Godfrey R
Circulation; 1994 Oct; 90(4):1811-9. PubMed ID: 7923666
[TBL] [Abstract][Full Text] [Related]
4. Comparative electrophysiologic findings between responders and nonresponders to class III antiarrhythmic drugs among patients with ventricular tachyarrhythmia.
Naitoh N; Washizuka T; Takahashi K; Miyajima T; Aizawa Y
Jpn Heart J; 1998 May; 39(3):307-19. PubMed ID: 9711182
[TBL] [Abstract][Full Text] [Related]
5. Prolongation of ventricular refractoriness by class Ia antiarrhythmic drugs in the prevention of ventricular tachycardia induction.
Kus T; Costi P; Dubuc M; Shenasa M
Am Heart J; 1990 Oct; 120(4):855-63. PubMed ID: 2220538
[TBL] [Abstract][Full Text] [Related]
6. Frequency-dependent electrophysiologic effects of amiodarone in humans.
Sager PT; Uppal P; Follmer C; Antimisiaris M; Pruitt C; Singh BN
Circulation; 1993 Sep; 88(3):1063-71. PubMed ID: 8353868
[TBL] [Abstract][Full Text] [Related]
7. Frequency-dependent electrophysiologic effects of d,l-sotalol and quinidine and modulation by beta-adrenergic stimulation.
Sager PT; Behboodikhah M
J Cardiovasc Electrophysiol; 1996 Feb; 7(2):102-12. PubMed ID: 8853020
[TBL] [Abstract][Full Text] [Related]
8. Reverse use dependence of human ventricular repolarization by chronic oral sotalol in monophasic action potential recordings.
Shimizu W; Kurita T; Suyama K; Aihara N; Kamakura S; Shimomura K
Am J Cardiol; 1996 May; 77(11):1004-8. PubMed ID: 8644624
[TBL] [Abstract][Full Text] [Related]
9. Electrophysiologic effects of intravenous MS-551, a novel class III antiarrhythmic agent, on human atrium and ventricle.
Naitoh N; Taneda K; Tagawa M; Furushima H; Yamaura M; Aizawa Y
Jpn Heart J; 1998 May; 39(3):297-305. PubMed ID: 9711181
[TBL] [Abstract][Full Text] [Related]
10. Differential effects of isoproterenol on sustained ventricular tachycardia before and during procainamide and quinidine antiarrhythmic drug therapy.
Markel ML; Miles WM; Luck JC; Klein LS; Prystowsky EN
Circulation; 1993 Mar; 87(3):783-92. PubMed ID: 8443899
[TBL] [Abstract][Full Text] [Related]
11. Frequency dependent effects of d-sotalol and amiodarone on the action potential duration of the human right ventricle.
Huikuri HV; Yli-Mäyry S
Pacing Clin Electrophysiol; 1992 Nov; 15(11 Pt 2):2103-7. PubMed ID: 1279607
[TBL] [Abstract][Full Text] [Related]
12. Electrophysiologic mechanisms of antiarrhythmic efficacy of a sotalol and class Ia drug combination: elimination of reverse use dependence.
Lee SD; Newman D; Ham M; Dorian P
J Am Coll Cardiol; 1997 Jan; 29(1):100-5. PubMed ID: 8996301
[TBL] [Abstract][Full Text] [Related]
13. Is the ventricular effective refractory period different when determined by incremental versus decremental scanning?: the effect of pacing cycle length, d-sotalol, and levcromakalim.
Leerssen HM; Vos MA; den Dulk K; van der Zande J; Wellens HJ
Pacing Clin Electrophysiol; 1994 Nov; 17(11 Pt 2):2084-9. PubMed ID: 7845822
[TBL] [Abstract][Full Text] [Related]
14. Na+ channel blockers vs class III antiarrhythmic drugs in treating sustained ventricular tachycardia: reversing and preventing as different electrophysiological mechanisms.
Masotti CS; Pierangeli A
Panminerva Med; 1999 Dec; 41(4):295-306. PubMed ID: 10705709
[TBL] [Abstract][Full Text] [Related]
15. The effect of vernakalant (RSD1235), an investigational antiarrhythmic agent, on atrial electrophysiology in humans.
Dorian P; Pinter A; Mangat I; Korley V; Cvitkovic SS; Beatch GN
J Cardiovasc Pharmacol; 2007 Jul; 50(1):35-40. PubMed ID: 17666913
[TBL] [Abstract][Full Text] [Related]
16. Isoproterenol antagonizes drug-induced prolongation of action potential duration in humans.
Newman D; Dorian P; Feder-Elituv R
Can J Physiol Pharmacol; 1993; 71(10-11):755-60. PubMed ID: 8143233
[TBL] [Abstract][Full Text] [Related]
17. Electrophysiological effects of MS-551, a new class III agent: comparison with dl-sotalol in dogs.
Sen L; Cui G; Sakaguchi Y; Singh BN
J Pharmacol Exp Ther; 1998 May; 285(2):687-94. PubMed ID: 9580614
[TBL] [Abstract][Full Text] [Related]
18. Comparison of electrophysiologic effects of intravenous E-4031 and MS-551, novel class III antiarrhythmic agents, in patients with ventricular tachyarrhythmias.
Naitoh N; Tagawa M; Yamaura M; Taneda K; Furushima H; Aizawa Y
Jpn Heart J; 1998 Jul; 39(4):457-67. PubMed ID: 9810296
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the effects of chronic oral therapy with atenolol and sotalol on ventricular monophasic action potential duration and effective refractory period.
Way BP; Forfar JC; Cobbe SM
Am Heart J; 1988 Sep; 116(3):740-6. PubMed ID: 3046277
[TBL] [Abstract][Full Text] [Related]
20. Steady-state and dynamic behavior of ventricular repolarization and refractoriness in the dog: the effect of multiple cycle length changes and d-sotalol administration.
Leerssen HM; Vos MA; den Dulk K; van der Zande J; Muijtjens AM; Begemann MJ; Wellens HJ
Pacing Clin Electrophysiol; 1998 Sep; 21(9):1766-77. PubMed ID: 9744441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
